net_left Phương Thức Thanh Toán

Roche's Alzheimer's drug fails to meet goal in long awaited trial

14 Tháng Mười Một 2022
Roche's Alzheimer's drug fails to meet goal in long awaited trial © Reuters. FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann
let atwWrapper,atwContainerWidth,atwSliderBox,atwTotalWidth; function initATWSlider() { atwWrapper = $('.relatedInstruments'); atwSliderBox = atwWrapper.find('.slider'); atwContainerWidth = atwWrapper.width(); atwTotalWidth = atwSliderBox.width(); if(window.domainId === '2' || window.domainId === '3'){ atwWrapper.find('.sliderRight').addClass('js-slider-prev'); atwWrapper.find('.sliderLeft').addClass('js-slider-next'); } else { atwWrapper.find('.sliderRight').addClass('js-slider-next'); atwWrapper.find('.sliderLeft').addClass('js-slider-prev'); } if(atwSliderBox.find('.instrumentBox').length > 6){ atwWrapper.find('.js-slider-next').fadeIn(600); } } function atwMoveRight() { atwWrapper.find('.js-slider-prev').fadeIn(150); $(".slider > :visible:first").hide(150) $(".slider > :visible:last").next().show(150); if(!$(".slider > :visible:last").next().find('.name')()){ atwWrapper.find('.js-slider-next').fadeOut(150); return; } } function atwMoveLeft() { atwWrapper.find('.js-slider-next').fadeIn(150); $(".slider > :visible:last").hide(150); $(".slider > :visible:first").prev().show(150); if(!$(".slider > :visible:first").prev().find('.name')()){ atwWrapper.find('.js-slider-prev').fadeOut(150); return; } } initATWSlider(); //update star icon on adding/removing instrument to/from specific watchlist atwWrapper.on('click', 'label.addRow', function() { let parent = $(this).parent(); let checkedPortfolio = false; parent.find('input[type=checkbox]').each(function () { if($(this).is(':checked')){ checkedPortfolio = true; } }); let closestStar = $(this).closest('.addToPortWrapper').find('.star'); if(checkedPortfolio){ closestStar.addClass('added'); }else{ closestStar.removeClass('added'); } }); //update star icon on creating new watchlist atwWrapper.find('.js-create-watchlist-portfolio').find('a.js-create').on('click',function () { let parent = $(this).parent(); let watchlistName = parent.find('input[type=text]').val(); if(!watchlistName){ return; } let star = $(this).closest('.addToPortWrapper').find('.star'); star.addClass('added'); }); //update star icon on adding new position atwWrapper.find('.js-create-holdings-portfolio').find('.js-submit').on('click',function () { let addPositionForm = $(this).closest('.addToPortfolioPop').find('.holdingsContent'); let amount = addPositionForm.find('.js-amount').val(); if(amount < 1){ return; } let star = $(this).closest('.addToPortWrapper').find('.star'); star.addClass('added'); }); atwWrapper.find('.instrumentBox').find('.shortInfo').on('click',function () { if(!window.ga){ return; } let pairId = $(this).parent().find('.js-add-to-portfolio').attr('data-pair-id'); let pairType = window.atwPairTypes[pairId]; window.ga('allSitesTracker.send', 'event', 'content', 'symbol link clicked', '', { "dimension147":"symbol_link_clicked", "dimension163":"click", "dimension148":"symbol", "dimension162":"content add to watchlist", "dimension161":"article page", "dimension142":"article", "dimension75":pairType, "dimension138":pairId, "dimension118":"2942761" }); window.open($(this).attr('data-href')); }); window.atwPairTypes = {"273":"Equities","6487":"Equities"};

By Ludwig Burger

(Reuters) -Roche's Alzheimer's drug candidate could not be shown to slow dementia progression in two drug trials, leaving rivals Biogen (NASDAQ:BIIB) and Eisai as leaders in a high-stakes race to launch a treatment for the memory-robbing disease.

Roche said in a statement on Monday that twin studies known as Graduate 1 and 2 had not reached their main goal of showing that the drug gantenerumab could preserve abilities such as remembering, solving problems, orientation and personal care in patients suffering from early stages of Alzheimer's disease.

The Swiss drugmaker conducted two identically designed studies, each with about 1,000 participants, who were examined and queried by physicians over more than two years. Within each study, volunteers were randomly assigned to receive either the injectable antibody drug gantenerumab or a placebo.

The drug was associated with a relative reduction in clinical decline of 8% in Graduate 1 and 6% in Graduate 2 compared with the placebo, but those results were not statistically reliable, the company said in a statement.

Credit Suisse analysts, who had seen a 20% chance of the drug reaching peak annual sales of $10 billion, described the trial failure as "unequivocal".

Berenberg analysts had put a 50% probability on gantenerumab achieving the $10 billion peak.

Roche shares fell 4.4% to their lowest in almost seven weeks.

Analysts have said the read-out from the trial would impact stock market confidence in Roche's research prowess, especially after lung cancer immunotherapy hopeful tiragolumab fell through in trials earlier this year, battering the company's shares.

"The development pipeline has disappointed a bit too often to keep the stock on a list of favourites," analysts at Luzerner Kantonalbank said in a research note.

Gantenerumab was designed to bind to aggregated forms of beta-amyloid and remove brain amyloid plaques, which are believed to play a crucial role in the slowly progressing dementia disease.

The setback will be an added challenge for CEO-designate Thomas Schinecker, Roche's head of diagnostics, who will be promoted in March. He will replace Severin Schwan, the chief executive who has led a successful campaign to diversify away from Roche's traditional focus on cancer.

The quest to develop an Alzheimer's drug, targeting beta-amyloid or other molecules, has been beset by a long list of study failures.

But rival Biogen in September scored a surprise trial success with an experimental Alzheimer's drug that it developed with Eisai, rebuilding confidence among industry executives and researchers in the beta-amyloid approach.

Biogen and Eisai said at the time their drug candidate lecanemab had slowed progression of the brain-wasting disease by 27% compared with a placebo in a large trial of patients in the early stages of Alzheimer's.

Roche released only the main outcome of the trials on Monday. It plans to present detailed data at the Clinical Trials on Alzheimer's Disease conference in San Francisco on Nov. 30.

Rachelle Doody, Roche's head of neurodegeneration, said she was very disappointed, adding that trial measures of amyloid removal were also lower than hoped.

“We will be showing that there is a relationship between the lowering of amyloid and the clinical outcomes. It’s just that when you don’t get the amyloid lowering that you expected you won’t get the clinical outcome that you expected," she told Reuters.

DIFFICULT TO DIAGNOSE

Most of the 55 million people suffering from dementia worldwide are likely to be affected by Alzheimer's disease, according to the World Health Organization. In 2030, dementia is expected to affect 78 million.

Alzheimer's is difficult to diagnose, especially during its early stages.

Germany's Morphosys would have received tiered royalties of about 2% to 3% on future gantenerumab sales from its early role in developing the drug. Its shares plunged 28%.

Royalty Pharma would have been entitled to about 3% to 4% of gantenerumab sales under a 2021 deal with Morphosys.

Eli Lilly (NYSE:LLY) is also working on an amyloid-targeting antibody drug, donanemab, with results of a key late-stage trial expected by mid-2023.

Để lại bình luận
Hot Auto Trade Bot Phương Thức Thanh Toán
BROKERS ĐƯỢC CẤP PHÉP
net_home_top Ai VIF
06-12-2022 00:38:16 (UTC+7)

EUR/USD

1.0504

-0.0034 (-0.32%)

Summary

↑ Sell

Moving Avg:

Buy (1)

Sell (11)

Indicators:

Buy (2)

Sell (6)

EUR/USD

1.0504

-0.0034 (-0.32%)

Summary

↑ Sell

Moving Avg:

Buy (1)

Sell (11)

Indicators:

Buy (2)

Sell (6)

GBP/USD

1.2184

-0.0103 (-0.83%)

Summary

↑ Sell

Moving Avg:

Buy (2)

Sell (10)

Indicators:

Buy (1)

Sell (8)

USD/JPY

136.49

+2.19 (+1.63%)

Summary

↑ Buy

Moving Avg:

Buy (7)

Sell (5)

Indicators:

Buy (6)

Sell (3)

AUD/USD

0.6711

-0.0078 (-1.16%)

Summary

↑ Sell

Moving Avg:

Buy (2)

Sell (10)

Indicators:

Buy (1)

Sell (10)

USD/CAD

1.3580

+0.0112 (+0.83%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (9)

Sell (1)

EUR/JPY

143.38

+1.85 (+1.31%)

Summary

↑ Sell

Moving Avg:

Buy (1)

Sell (11)

Indicators:

Buy (2)

Sell (7)

EUR/CHF

0.9893

+0.0022 (+0.22%)

Summary

Neutral

Moving Avg:

Buy (11)

Sell (1)

Indicators:

Buy (2)

Sell (3)

Gold Futures

1,782.40

-27.20 (-1.50%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (10)

Silver Futures

22.387

-0.863 (-3.71%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (10)

Copper Futures

3.7933

-0.0572 (-1.49%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (9)

Crude Oil WTI Futures

78.53

-1.45 (-1.81%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (1)

Sell (9)

Brent Oil Futures

84.17

-1.40 (-1.64%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (1)

Sell (9)

Natural Gas Futures

5.677

-0.604 (-9.62%)

Summary

↑ Sell

Moving Avg:

Buy (1)

Sell (11)

Indicators:

Buy (1)

Sell (6)

US Coffee C Futures

163.30

+0.70 (+0.43%)

Summary

↑ Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (9)

Sell (0)

Euro Stoxx 50

3,956.53

-21.37 (-0.54%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (8)

S&P 500

4,011.00

-60.70 (-1.49%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (11)

DAX

14,447.61

-81.78 (-0.56%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (7)

FTSE 100

7,567.54

+11.31 (+0.15%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (8)

Hang Seng

19,518.29

+842.94 (+4.51%)

Summary

Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (4)

Sell (2)

US Small Cap 2000

1,842.35

-47.63 (-2.52%)

Summary

Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (5)

Sell (1)

IBEX 35

8,370.10

-7.80 (0.00%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (10)

BASF SE NA O.N.

47.970

-0.760 (-1.56%)

Summary

Sell

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (0)

Sell (9)

Bayer AG NA

53.09

-1.75 (-3.19%)

Summary

↑ Buy

Moving Avg:

Buy (10)

Sell (2)

Indicators:

Buy (6)

Sell (1)

Allianz SE VNA O.N.

203.00

+0.35 (+0.17%)

Summary

Buy

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (6)

Sell (3)

Adidas AG

122.06

-2.20 (-1.77%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (3)

Sell (4)

Deutsche Lufthansa AG

7.766

+0.028 (+0.36%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (2)

Siemens AG Class N

135.44

+0.74 (+0.55%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (2)

Deutsche Bank AG

10.150

+0.126 (+1.26%)

Summary

Neutral

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (4)

Sell (3)

    EUR/USD 1.0504 ↑ Sell  
    GBP/USD 1.2184 ↑ Sell  
    USD/JPY 136.49 ↑ Buy  
    AUD/USD 0.6711 ↑ Sell  
    USD/CAD 1.3580 ↑ Buy  
    EUR/JPY 143.38 ↑ Sell  
    EUR/CHF 0.9893 Neutral  
    Gold 1,782.40 ↑ Sell  
    Silver 22.387 ↑ Sell  
    Copper 3.7933 ↑ Sell  
    Crude Oil WTI 78.53 ↑ Sell  
    Brent Oil 84.17 ↑ Sell  
    Natural Gas 5.677 ↑ Sell  
    US Coffee C 163.30 ↑ Buy  
    Euro Stoxx 50 3,956.53 ↑ Sell  
    S&P 500 4,011.00 ↑ Sell  
    DAX 14,447.61 ↑ Sell  
    FTSE 100 7,567.54 ↑ Sell  
    Hang Seng 19,518.29 Buy  
    Small Cap 2000 1,842.35 Buy  
    IBEX 35 8,370.10 ↑ Sell  
    BASF 47.970 Sell  
    Bayer 53.09 ↑ Buy  
    Allianz 203.00 Buy  
    Adidas 122.06 ↑ Sell  
    Lufthansa 7.766 ↑ Buy  
    Siemens AG 135.44 ↑ Buy  
    Deutsche Bank AG 10.150 Neutral  
Mua/Bán 1 chỉ SJC
# So hôm qua # Chênh TG
SJC Eximbank6,610/ 6,680
(0/ 0) # 1,473
SJC HCM6,625/ 6,705
(0/ 0) # 1,500
SJC Hanoi6,625/ 6,707
(0/ 0) # 1,502
SJC Danang6,625/ 6,707
(0/ 0) # 1,502
SJC Nhatrang6,625/ 6,707
(0/ 0) # 1,502
SJC Cantho6,625/ 6,707
(0/ 0) # 1,502
Cập nhật 06-12-2022 00:38:18
Xem lịch sử giá vàng SJC: nhấn đây!
ↀ Giá vàng thế giới
$1,770.64 -28.21 -1.57%
Live 24 hour Gold Chart
ʘ Giá bán lẻ xăng dầu
Sản phẩm Vùng 1 Vùng 2
RON 95-V23.83024.300
RON 95-III22.70023.150
E5 RON 92-II21.67022.100
DO 0.05S23.21023.670
DO 0,001S-V25.19025.690
Dầu hỏa 2-K23.56024.030
ↂ Giá dầu thô thế giới
WTI $78.68 +3.78 4.80%
Brent $84.14 +2.61 3.01%
$ Tỷ giá Vietcombank
Ngoại tệMua vàoBán ra
USD23.760,0024.070,00
EUR24.574,8925.950,11
GBP28.594,5429.812,86
JPY172,03182,11
KRW15,9819,47
Cập nhật lúc 18:53:14 05/12/2022
Xem bảng tỷ giá hối đoái
Phương Thức Thanh Toán